Drug Profile
EDC 8
Alternative Names: EDC-8Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Wisconsin Alumni Research Foundation
- Developer Centrose
- Class Antineoplastics; Drug conjugates; Glycosides; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action CD38 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer; Inflammation
Highest Development Phases
- Preclinical Acute myeloid leukaemia
- Discontinued Inflammation
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Inflammation in USA (unspecified route) (Centrose Pharma pipeline, September 2023)
- 12 Sep 2023 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route), prior to September 2023 (Centrose Pharma pipeline, September 2023)
- 12 Sep 2023 Pharmacodynamics data from the preclinical trial in Acute myeloid leukaemia released by Centrose Pharma, prior to September 2023 (Centrose Pharma pipeline, September 2023)